| Entry |
|
|---|
| Name |
Busulfan (JP17/USP/INN);
Myleran (TN) |
|---|
| Product |
|
|---|
| Generic |
BUSULFAN (Accord Healthcare), BUSULFAN (American Regent), BUSULFAN (Amneal Pharmaceuticals LLC), BUSULFAN (Apotex Corp.), BUSULFAN (Armas Pharmaceuticals), BUSULFAN (Athenex Pharmaceutical Division), BUSULFAN (CELLTRION USA), BUSULFAN (Fresenius Kabi USA), BUSULFAN (Hospira), BUSULFAN (Meitheal Pharmaceuticals), BUSULFAN (Mylan Institutional LLC), BUSULFAN (Pharmascience), BUSULFAN (Sagent Pharmaceuticals) |
|---|
| Formula |
C6H14O6S2
|
|---|
| Exact mass |
246.0232
|
|---|
| Mol weight |
246.3018
|
|---|
| Structure |
|
|---|
| Simcomp |
|
|---|
| Class |
Antineoplastic
DG01677 Alkylating agent
DG01721 Methanesulfonate derivative
|
|---|
| Remark |
| Therapeutic category: | 4213 |
|
|---|
| Efficacy |
Antineoplastic, Alkylating agent, Immunosuppressant |
|---|
| Disease |
Chronic myelogenous (myeloid, myelocytic, granulocytic) leukemia [DS: H00004] |
|---|
| Comment |
Busulfan is clearly less effective in patients with chronic myelogenous leukemia who lack the Philadelphia (Ph1) chromosome.
|
|---|
| Target |
DNA |
|---|
| Interaction |
|
|---|
| Structure map |
| map07040 | Antineoplastics - alkylating agents |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01A ALKYLATING AGENTS
L01AB Alkyl sulfonates
L01AB01 Busulfan
D00248 Busulfan (JP17/USP/INN) <JP/US>
USP drug classification [BR:br08302]
Antineoplastics
Alkylating Agents
Busulfan
D00248 Busulfan (JP17/USP/INN)
Therapeutic category of drugs in Japan [BR:br08301]
4 Agents affecting cellular function
42 Antineoplastics
421 Alkylating agents
4213 Sulfonate esters
D00248 Busulfan (JP17/USP/INN)
Drugs listed in the Japanese Pharmacopoeia [BR:br08311]
Chemicals
D00248 Busulfan
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D00248
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
| KCF data |
ATOM 14
1 S4a S 16.2149 -21.9100
2 O2a O 17.4273 -22.6100
3 C1b C 18.6397 -21.9100
4 C1b C 19.8522 -22.6100
5 C1b C 21.0646 -21.9100
6 C1b C 22.2770 -22.6100
7 O2a O 23.4895 -21.9100
8 S4a S 24.7019 -22.6100
9 C1a C 15.0024 -21.2100
10 O3c O 16.9209 -20.6867
11 O3c O 15.5214 -23.1115
12 C1a C 25.9144 -23.3100
13 O3c O 25.4243 -21.4059
14 O3c O 23.9838 -23.8069
BOND 13
1 1 2 1
2 2 3 1
3 3 4 1
4 4 5 1
5 5 6 1
6 6 7 1
7 7 8 1
8 1 9 1
9 1 10 2
10 1 11 2
11 8 12 1
12 8 13 2
13 8 14 2
|
|---|
